<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36494763</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2397-0642</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Global health research and policy</Title><ISOAbbreviation>Glob Health Res Policy</ISOAbbreviation></Journal><ArticleTitle>Effective strategies against COVID-19 and the importance of infection sequelae.</ArticleTitle><Pagination><StartPage>49</StartPage><MedlinePgn>49</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">49</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41256-022-00283-x</ELocationID><Abstract><AbstractText>COVID-19 is a serious threat to human health and development. The acute burden of the pandemic includes more than 18.2 million deaths worldwide, and is unprecedented in modern times. This represents only a fraction of the total burden, as it excludes infection sequelae. An effective global strategic paradigm has been missing throughout the pandemic. The 'flattening the curve' approach neglected the importance of infection sequelae, and being centered on healthcare capacity was conceptually contrary to a people-centered health system. In March 2022, the World Health Organization revised its pandemic approach, importantly shifting emphasis away from managing transmission and towards prevention. Despite limitations, this now recognizes the role of infection sequelae, whose impact is becoming clearer in both variety and scale. Drawing on the foundational concepts of Sun Tzu and Carl von Clausewitz, most country approaches do not qualify as strategies, but rather as operational plans. They are also largely ineffective, neglecting infection sequelae, viral evolution dangers and other parameters. The purpose of this article is to summarize the evidence on COVID-19 infection sequelae, and alongside other contextual parameters use this to motivate that infection should be prevented. This is then used to answer the question: What is an effective strategy against COVID-19?</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khalife</LastName><ForeName>Jade</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8765-0142</Identifier><AffiliationInfo><Affiliation>Social Medicine and Global Health, Faculty of Medicine, Lund University, Jan Waldenstr&#xf6;ms Gata 35, 214 28, Malm&#xf6;, Sweden. jade.khalife@med.lu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Glob Health Res Policy</MedlineTA><NlmUniqueID>101705789</NlmUniqueID><ISSNLinking>2397-0642</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chronic disease</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Sequelae</Keyword><Keyword MajorTopicYN="N">Strategy</Keyword></KeywordList><CoiStatement>The author declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36494763</ArticleId><ArticleId IdType="pmc">PMC9733266</ArticleId><ArticleId IdType="doi">10.1186/s41256-022-00283-x</ArticleId><ArticleId IdType="pii">10.1186/s41256-022-00283-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, Aravkin AY, Bisignano C, Barber RM, Alam T, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020&#x2013;21. The Lancet. 2022;399(10334):1513&#x2013;1536. doi: 10.1016/S0140-6736(21)02796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Director-General's opening remarks at the media briefing on COVID-19&#x2014;18 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---18-march-2020</Citation></Reference><Reference><Citation>Khalife J, VanGennep D. COVID-19 herd immunity in the absence of a vaccine: an irresponsible approach. Epidemiol Health. 2021;43:e2021012&#x2013;e2021010. doi: 10.4178/epih.e2021012.</Citation><ArticleIdList><ArticleId IdType="doi">10.4178/epih.e2021012</ArticleId><ArticleId IdType="pmc">PMC8060517</ArticleId><ArticleId IdType="pubmed">33541010</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusselaers N, Steadson D, Bjorklund K, Breland S, Stilhoff S&#xf6;rensen J, Ewing A, Bergmann S, Steineck G. Evaluation of science advice during the COVID-19 pandemic in Sweden. Humanit Soc Sci Commun. 2022;9(1):91. doi: 10.1057/s41599-022-01097-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1057/s41599-022-01097-5</ArticleId><ArticleId IdType="pmc">PMC9284503</ArticleId><ArticleId IdType="pubmed">35856700</ArticleId></ArticleIdList></Reference><Reference><Citation>Denmark Covid restrictions lifted despite increase in cases. https://www.bbc.com/news/world-europe-60215200</Citation></Reference><Reference><Citation>World Health Organization . Strategic preparedness, readiness and response plan to end the global COVID-19 emergency in 2022. Geneva: World Health Organization; 2022.</Citation></Reference><Reference><Citation>Jimenez JL, Marr LC, Randall K, Ewing ET, Tufekci Z, Greenhalgh T, Tellier R, Tang JW, Li Y, Morawska L, et al. What were the historical reasons for the resistance to recognizing airborne transmission during the COVID-19 pandemic? Indoor Air. 2022;32(8):e13070. doi: 10.1111/ina.13070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ina.13070</ArticleId><ArticleId IdType="pmc">PMC9538841</ArticleId><ArticleId IdType="pubmed">36040283</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022 doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, et al. Post-COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years&#x2014;United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep. 2022;71:713. doi: 10.15585/mmwr.mm7121e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId><ArticleId IdType="pmc">PMC9368731</ArticleId><ArticleId IdType="pubmed">35925799</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022 doi: 10.1016/S2213-8587(22)00044-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Montefusco L, Ben Nasr M, D&#x2019;Addio F, Loretelli C, Rossi A, Pastore I, Daniele G, Abdelsalam A, Maestroni A, Dell&#x2019;Acqua M, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3(6):774&#x2013;785. doi: 10.1038/s42255-021-00407-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-021-00407-6</ArticleId><ArticleId IdType="pmc">PMC9931026</ArticleId><ArticleId IdType="pubmed">34035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, Pavkov ME, Rolka DB, Wiltz JL, Bull-Otterson L, et al. Risk for newly diagnosed diabetes &gt;30 days after SARS-CoV-2 infection among persons aged &lt;18 years&#x2014;United States, March 1, 2020&#x2013;June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):59&#x2013;65. doi: 10.15585/mmwr.mm7102e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7102e2</ArticleId><ArticleId IdType="pmc">PMC8757617</ArticleId><ArticleId IdType="pubmed">35025851</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. 2022 doi: 10.1038/s41591-022-02001-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02001-z</ArticleId><ArticleId IdType="pmc">PMC9671811</ArticleId><ArticleId IdType="pubmed">36138154</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, Lange F, Andersson JLR, Griffanti L, Duff E, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022 doi: 10.1038/s41586-022-04569-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, Guis S, Barthelemy F, Habert P, Ceccaldi M, et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48(9):2823&#x2013;2833. doi: 10.1007/s00259-021-05215-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand A, Campion J-Y, Lepine A, Bosdure E, Luciani L, Cammilleri S, Chabrol B, Guedj E. Similar patterns of [18F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series. Eur J Nucl Med Mol Imaging. 2021 doi: 10.1007/s00259-021-05528-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05528-4</ArticleId><ArticleId IdType="pmc">PMC8376118</ArticleId><ArticleId IdType="pubmed">34414470</ArticleId></ArticleIdList></Reference><Reference><Citation>Charnley M, Islam S, Bindra GK, Engwirda J, Ratcliffe J, Zhou J, Mezzenga R, Hulett MD, Han K, Berryman JT, et al. Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19. Nat Commun. 2022;13(1):3387. doi: 10.1038/s41467-022-30932-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30932-1</ArticleId><ArticleId IdType="pmc">PMC9189797</ArticleId><ArticleId IdType="pubmed">35697699</ArticleId></ArticleIdList></Reference><Reference><Citation>Semerdzhiev SA, Fakhree MAA, Segers-Nolten I, Blum C, Claessens MMAE. Interactions between SARS-CoV-2 N-protein and &#x3b1;-synuclein accelerate amyloid formation. bioRxiv. 2021 doi: 10.1101/2021.04.12.439549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.12.439549</ArticleId><ArticleId IdType="pmc">PMC8739828</ArticleId><ArticleId IdType="pubmed">34860005</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Boutajangout A, Masurkar AV, Betensky RA, Ge Y, Vedvyas A, Debure L, Moreira A, Lewis A, Huang J, et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia. Alzheimers Dement. 2022;18(5):899&#x2013;910. doi: 10.1002/alz.12556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12556</ArticleId><ArticleId IdType="pmc">PMC9011610</ArticleId><ArticleId IdType="pubmed">35023610</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416&#x2013;427. doi: 10.1016/s2215-0366(21)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn&#xfa;sd&#xf3;ttir I, Lovik A, Unnarsd&#xf3;ttir AB, McCartney D, Ask H, K&#xf5;iv K, Christoffersen LAN, Johnson SU, Hauksd&#xf3;ttir A, Fawns-Ritchie C, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. Lancet Public Health. 2022;7(5):e406&#x2013;e416. doi: 10.1016/S2468-2667(22)00042-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(22)00042-1</ArticleId><ArticleId IdType="pmc">PMC8920517</ArticleId><ArticleId IdType="pubmed">35298894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325&#x2013;328. doi: 10.1016/j.chom.2020.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.02.001</ArticleId><ArticleId IdType="pmc">PMC7154514</ArticleId><ArticleId IdType="pubmed">32035028</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak IWC, Chu CM, Pan PC, Yiu MGC, Chan VL. Long-term psychiatric morbidities among SARS survivors. Gen Hosp Psychiatry. 2009;31(4):318&#x2013;326. doi: 10.1016/j.genhosppsych.2009.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2009.03.001</ArticleId><ArticleId IdType="pmc">PMC7112501</ArticleId><ArticleId IdType="pubmed">19555791</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283&#x2013;288. doi: 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, F&#xfc;rst J, Schulze-Rothe S, Wallukat A, H&#xf6;nicke A-S, M&#xfc;ller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100&#x2013;100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Li W, Wang T, Ran D, Davalos V, Planas-Serra L, Pujol A, Esteller M, Wang X, Yu H. Accelerated biological aging in COVID-19 patients. Nat Commun. 2022;13(1):2135. doi: 10.1038/s41467-022-29801-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29801-8</ArticleId><ArticleId IdType="pmc">PMC9018863</ArticleId><ArticleId IdType="pubmed">35440567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongelli A, Barbi V, Gottardi Zamperla M, Atlante S, Forleo L, Nesta M, Massetti M, Pontecorvi A, Nanni S, Farsetti A, et al. Evidence for biological age acceleration and telomere shortening in COVID-19 survivors. Int J Mol Sci. 2021;22(11):6151. doi: 10.3390/ijms22116151.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22116151</ArticleId><ArticleId IdType="pmc">PMC8201243</ArticleId><ArticleId IdType="pubmed">34200325</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, Juno JA, Burrell LM, Kent SJ, Dore GJ, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022 doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Uusk&#xfc;la A, J&#xfc;rgenson T, Pisarev H, Kolde R, Meister T, Tisler A, Suija K, Kalda R, Piirsoo M, Fischer K. Long-term mortality following SARS-CoV-2 infection: a national cohort study from Estonia. Lancet Reg Health &#x2013; Europe. 2022 doi: 10.1016/j.lanepe.2022.100394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100394</ArticleId><ArticleId IdType="pmc">PMC9051903</ArticleId><ArticleId IdType="pubmed">35505834</ArticleId></ArticleIdList></Reference><Reference><Citation>Mainous AG, Rooks BJ, Wu V, Orlando FA. COVID-19 post-acute sequelae among adults: 12 month mortality risk. Front Med. 2021 doi: 10.3389/fmed.2021.778434.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.778434</ArticleId><ArticleId IdType="pmc">PMC8671141</ArticleId><ArticleId IdType="pubmed">34926521</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa LC, Goncalves TL, de Araujo LP, de Oliveira Rosario LV, Ferrer VP. Endothelial cells and SARS-CoV-2: an intimate relationship. Vascul Pharmacol. 2021;137:106829&#x2013;106829. doi: 10.1016/j.vph.2021.106829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2021.106829</ArticleId><ArticleId IdType="pmc">PMC7834309</ArticleId><ArticleId IdType="pubmed">33422689</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370(6518):856&#x2013;860. doi: 10.1126/science.abd2985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd2985</ArticleId><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Tav&#x10d;ar P, Potokar M, Kolenc M, Korva M, Av&#x161;i&#x10d;-&#x17d;upanc T, Zorec R, Jorga&#x10d;evski J. Neurotropic viruses, astrocytes, and COVID-19. Front Cell Neurosci. 2021;15:662578&#x2013;662578. doi: 10.3389/fncel.2021.662578.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.662578</ArticleId><ArticleId IdType="pmc">PMC8062881</ArticleId><ArticleId IdType="pubmed">33897376</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022 doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5. https://www.drugs.com/clinical_trials/moderna-announces-bivalent-booster-mrna-1273-214-demonstrates-potent-neutralizing-antibody-response-20231.html</Citation></Reference><Reference><Citation>Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19</Citation></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022 doi: 10.1038/s41591-022-02051-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022 doi: 10.1038/s41591-022-01810-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Ayuzo del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022;12(1):9950. doi: 10.1038/s41598-022-13495-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13495-5</ArticleId><ArticleId IdType="pmc">PMC9226045</ArticleId><ArticleId IdType="pubmed">35739136</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapani G, Verlato G, Bertino E, Maiocco G, Vesentini R, Spadavecchia A, Dess&#xec; A, Fanos V. Long COVID-19 in children: an Italian cohort study. Ital J Pediatr. 2022;48(1):83. doi: 10.1186/s13052-022-01282-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-022-01282-x</ArticleId><ArticleId IdType="pmc">PMC9163526</ArticleId><ArticleId IdType="pubmed">35659358</ArticleId></ArticleIdList></Reference><Reference><Citation>Qasmieh SA, Robertson MM, Teasdale CA, Kulkarni SG, Jones H, McNairy M, Borrell LN, Nash D. The prevalence of SARS-CoV-2 infection and long COVID in US adults during the BA.5 surge, June&#x2013;July 2022. medRxiv. 2022 doi: 10.1101/2022.09.04.22279588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.09.04.22279588</ArticleId><ArticleId IdType="pmc">PMC9940463</ArticleId><ArticleId IdType="pubmed">36813250</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, Primus-de Jong C, Cleemput I, Van den Heede K. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54(1):1473&#x2013;1487. doi: 10.1080/07853890.2022.2076901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P, Casari G, Townsend L, O&#x2019;Farrelly C, Tancevski I, L&#xf6;ffler-Ragg J, Mogensen TH, Casanova JL, Abel L, Aiuti A, et al. Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med. 2022;28(5):879&#x2013;882. doi: 10.1038/s41591-022-01766-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01766-7</ArticleId><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, Hall E, Herrera M, Parikh P, Guevara-Coto J, et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol. 2022 doi: 10.3389/fimmu.2021.746021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sablone S, Solarino B, Ferorelli D, Benevento M, Chironna M, Loconsole D, Sallustio A, Dell'Erba A, Introna F. Post-mortem persistence of SARS-CoV-2: a preliminary study. Forensic Sci Med Pathol. 2021;17(3):403&#x2013;410. doi: 10.1007/s12024-021-00375-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12024-021-00375-z</ArticleId><ArticleId IdType="pmc">PMC8105695</ArticleId><ArticleId IdType="pubmed">33963967</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Carballa A, Martin&#xf3;n-Torres F, Salas A. Is SARS-CoV-2 an oncogenic virus? J Infect. 2022 doi: 10.1016/j.jinf.2022.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.08.005</ArticleId><ArticleId IdType="pmc">PMC9361571</ArticleId><ArticleId IdType="pubmed">35961462</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics U. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 June 2022; 2022.</Citation></Reference><Reference><Citation>R. T. Long Covid forces 10&#x2009;000 NHS staff off sick for longer than three months. In: Independent. 2022.</Citation></Reference><Reference><Citation>Saunders M. The route back to 2% inflation. London: Bank of England; 2022.</Citation></Reference><Reference><Citation>Bharat Biotech&#x2019;s iNCOVACC world&#x2019;s first Intra Nasal vaccine receives approval for emergency use in India. https://www.bharatbiotech.com/images/press/Bharat-Biotech-iNCOVACC-Worlds-First-Intra-Nasal-Vaccine-Receives-Approval.pdf</Citation></Reference><Reference><Citation>CanSinoBIO's Convidecia Air&#x2122; Receives Approval in China. https://www.cansinotech.com/html/1///179/180/1100.html</Citation></Reference><Reference><Citation>The COVID-19 vaccine tracker. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</Citation></Reference><Reference><Citation>Alizon S, Hurford A, Mideo N, Van Baalen M. Virulence evolution and the trade-off hypothesis: history, current state of affairs and the future. J Evol Biol. 2009;22(2):245&#x2013;259. doi: 10.1111/j.1420-9101.2008.01658.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1420-9101.2008.01658.x</ArticleId><ArticleId IdType="pubmed">19196383</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzourakis A. COVID-19: endemic doesn't mean harmless. Nature. 2022;601(7894):485. doi: 10.1038/d41586-022-00155-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-00155-x</ArticleId><ArticleId IdType="pubmed">35075305</ArticleId></ArticleIdList></Reference><Reference><Citation>UK SAGfE-. Long term evolution of SARS-CoV-2, 26 July. In.; 2021.</Citation></Reference><Reference><Citation>Sun B, Giles L. Sun Tzu on the art of war: the oldest military treatise in the world. Champaign: Project Gutenberg, NetLibrary; 1990.</Citation></Reference><Reference><Citation>von Clausewitz C. On war. Ware, Hertfordshire: Wordsworth Editions Limited; 1997.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>